Is PT-141 (Bremelanotide) Legal in New York?

The Short Answer: Yes, With a Valid Prescription

PT-141 (Bremelanotide) is legal in New York for patients who hold a valid prescription issued by a New York State-licensed clinician. The FDA approved Bremelanotide under the brand name Vyleesi in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it a Schedule-free but prescription-only drug under federal law. [1]

Possession or use without a prescription is not a criminal act the way a scheduled narcotic would be, but purchasing it from an unregulated source or a compounding pharmacy that does not comply with current FDA guidance creates meaningful legal and safety exposure for both patient and provider.

Why the 2025 Bulk-Compounding Ban Changes Everything

The FDA finalized its decision to remove Bremelanotide from the list of bulk drug substances that may be used by 503A compounding pharmacies. That rule became effective in January 2025. [2] Before that date, many telehealth clinics in New York prescribed compounded injectable Bremelanotide as a lower-cost alternative to Vyleesi. That pathway is now closed under federal law.

A 503B outsourcing facility cannot use a bulk substance that the FDA has affirmatively removed from consideration either, because 503B facilities are held to an even stricter standard than 503A pharmacies. [3] Any New York pharmacy or out-of-state mail-order pharmacy shipping compounded Bremelanotide into New York after the effective date is operating outside federal law.

What "Prescription-Only" Means Under New York Law

New York Education Law §6810 classifies prescription drugs as those requiring a practitioner's order before dispensing. [4] Bremelanotide, as an FDA-approved prescription product, falls squarely into this class. Dispensing it without a valid prescription exposes the pharmacist or seller to disciplinary action by the New York State Board of Pharmacy, civil liability, and potential criminal misbranding charges under the federal Food, Drug, and Cosmetic Act. [5]

Patients who buy PT-141 from research-chemical websites, gray-market peptide vendors, or overseas suppliers are purchasing a product that has not been reviewed for sterility, potency, or identity. The FDA has issued multiple warning letters to peptide sellers marketing products labeled "for research use only" that contain active pharmaceutical ingredients. [6]

Federal Framework: FDA Approval and Scheduling Status

Bremelanotide's legal profile at the federal level rests on two pillars: its approved drug status and its non-scheduled classification.

FDA-Approved Indication and Label

The FDA approved Vyleesi (Bremelanotide injection, 1.75 mg/0.3 mL) on June 21, 2019, based on two Phase 3 randomized controlled trials. [1] The approved indication is acquired, generalized HSDD in premenopausal women. The label carries a contraindication for patients with cardiovascular disease because Bremelanotide causes transient increases in blood pressure (mean increase of approximately 6 mmHg systolic and 3 mmHg diastolic lasting roughly 12 hours). [1]

The drug works through melanocortin receptor agonism, primarily MC3R and MC4R in the central nervous system, rather than through a vascular or hormonal mechanism. [7] That mechanism distinguishes it from phosphodiesterase inhibitors and places it in a pharmacological class with no current DEA scheduling.

DEA Scheduling: Not a Controlled Substance

The DEA has not placed Bremelanotide on any schedule under the Controlled Substances Act. [8] This means federal law does not criminalize possession the way it would for a Schedule I or Schedule II substance. However, "not scheduled" does not mean "unregulated." The drug remains subject to the full suite of FDA prescription-drug regulations, and any entity distributing it as a drug without proper authorization violates the FD&C Act. [5]

The Bulk-Compounding Decision in Detail

The FDA's 503A bulks list process requires that a substance nominated for compounding either appear on the FDA's positive list or not have been affirmatively excluded. Bremelanotide was reviewed and removed from consideration, meaning compounding pharmacies may no longer use bulk Bremelanotide as a starting material. [2]

The FDA's stated rationale included the existence of an approved drug product (Vyleesi) that makes compounding unnecessary for most patients and concerns about the quality of bulk peptide materials entering the supply chain. [2] Clinicians who still want to prescribe Bremelanotide for off-label uses in men (erectile dysfunction or low libido) face a more complicated path now that the compounded route is closed, because Vyleesi's label covers only premenopausal women with HSDD.

New York State Framework: Pharmacy Board and Medical Practice Act

New York State Board of Pharmacy Rules

The New York State Board of Pharmacy operates under the authority of the New York State Education Department and enforces rules consistent with federal drug law. Pharmacies licensed in New York must dispense prescription drugs only pursuant to a valid prescription and must not dispense drugs that violate FDA manufacturing or compounding standards. [4]

A New York-licensed 503A compounding pharmacy that continued to compound Bremelanotide after the January 2025 ban would be in violation of federal law, which New York pharmacy regulations require compliance with. The Board has authority to revoke pharmacy licenses for such violations. [4]

Medical Practice Act and Prescriber Obligations

New York's medical practice framework (Education Law Article 131) requires physicians to practice within the standard of care. [9] Prescribing an off-label use of Bremelanotide (for example, to a man with low libido or to a postmenopausal woman) is not automatically prohibited, but the prescriber must document medical necessity and informed consent, particularly given the transient cardiovascular effects noted in the prescribing label. [1]

The North American Menopause Society's 2022 position statement on sexual dysfunction notes that evidence for Bremelanotide in postmenopausal women is limited, stating directly: "Bremelanotide has not been studied adequately in postmenopausal women, and its use in this population remains off-label with uncertain benefit-risk balance." [10] A New York prescriber offering it to a postmenopausal patient should document a careful risk-benefit discussion.

Telehealth Prescribing in New York

New York's telehealth statute (Public Health Law §2999-cc) allows clinicians to prescribe prescription drugs, including Bremelanotide, via a telehealth encounter, provided the prescriber holds an active New York State license and has established a valid patient-provider relationship. [11] The Ryan Haight Act, which restricts controlled-substance prescribing via telehealth, does not apply to Bremelanotide because it is not a controlled substance. [8]

This means a patient in Manhattan or Buffalo can legally receive a Vyleesi prescription through a telehealth visit with a New York-licensed provider. The prescription must be transmitted to a licensed pharmacy that stocks Vyleesi.

How to Get PT-141 (Bremelanotide) Legally in New York

Step 1: Consult a New York-Licensed Clinician

The first step is an evaluation with an MD, DO, nurse practitioner, or physician assistant holding prescriptive authority under a New York license. The evaluation should cover sexual health history, cardiovascular risk (given the transient BP increase), current medications, and whether the HSDD diagnosis fits the FDA-approved indication. Clinicians generally use validated tools such as the Female Sexual Function Index (FSFI) to document diagnosis. [12]

Step 2: Obtain a Valid Prescription for Vyleesi

If the clinician determines Bremelanotide is appropriate, they will write a prescription for brand-name Vyleesi (1.75 mg subcutaneous autoinjector). As of January 2025, compounded alternatives are no longer a lawful option. The prescription can be filled at any New York-licensed retail or specialty pharmacy that carries or can order Vyleesi.

Step 3: Verify the Pharmacy's Credentials

Patients should confirm their pharmacy holds an active New York State license. The New York State Education Department's online verification tool allows anyone to check a pharmacy's license status in real time. [4] For mail-order fulfillment, the pharmacy must be licensed in its home state and either licensed or registered in New York as an out-of-state pharmacy.

The table below summarizes the legal access pathways available to New York patients as of 2025.

| Access Route | Legal Status Post-Jan 2025 | Notes | |---|---|---| | Brand Vyleesi via in-person prescription | Legal | Standard pathway | | Brand Vyleesi via telehealth prescription | Legal | Provider must be NY-licensed | | Compounded Bremelanotide via 503A pharmacy | Not permitted | Removed from FDA bulks list | | Compounded Bremelanotide via 503B outsourcing facility | Not permitted | Same FDA restriction applies | | Research-chemical / gray-market peptide vendor | Not permitted | No prescription, no pharmaceutical oversight | | International online pharmacy (unlicensed) | Not permitted | Violates FD&C Act; FDA has enforcement authority |

Clinical Profile: What Patients and Prescribers Should Know

Efficacy Data from Phase 3 Trials

The two key Phase 3 trials (RECONNECT studies, combined N=1,247) showed that Bremelanotide produced a statistically significant increase in the number of satisfying sexual events per month compared to placebo (mean difference approximately 0.5 events per 28 days, P<0.001) and a significant reduction in FSFI distress scores. [13] The effect size is modest, and clinicians should communicate this clearly during the consent process.

Responder analysis from the RECONNECT studies showed that approximately 25% of Bremelanotide-treated patients achieved a clinically meaningful improvement in the FSFI desire domain versus approximately 17% in the placebo group. [13]

Safety Considerations Relevant to New York Prescribers

The most common adverse effects in the RECONNECT trials were nausea (40.1% Bremelanotide vs. 10.5% placebo), flushing (20.2% vs. 3.6%), and injection-site reactions. [1] The transient blood pressure increase means the drug is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension, consistent with FDA label guidance. [1]

The American Heart Association's scientific statement on sexual activity and cardiovascular disease advises that any drug affecting hemodynamics, including Bremelanotide, requires cardiovascular risk stratification before prescribing. [14] New York prescribers should obtain a recent blood pressure measurement and review cardiovascular history before initiating therapy.

Use in Men: Off-Label and Now Access-Restricted

Bremelanotide gained early attention for potential use in men with erectile dysfunction or low libido based on early Phase 2 data. [7] The FDA approved it only for premenopausal women with HSDD. Off-label prescribing for men is not prohibited, but since the compounded form is no longer available and Vyleesi is labeled for women, male patients face a practical barrier. A prescriber writing Vyleesi off-label for a male patient should document the rationale and discuss alternatives including FDA-approved phosphodiesterase-5 inhibitors. [15]

Gray-Market PT-141: Risks Beyond Legality

Peptide Purity and Contamination

Peptides sold through research-chemical websites are not manufactured under FDA Good Manufacturing Practice standards. Independent laboratory analyses of gray-market peptide products have identified incorrect active ingredient concentrations, microbial contamination, and the presence of unlabeled substances. [6] The FDA's warning letter database contains multiple enforcement actions against peptide suppliers for exactly these violations. [6]

Legal Risk to the Consumer

A patient purchasing gray-market PT-141 in New York does not face criminal drug charges because Bremelanotide is not scheduled. However, they may still face issues if the product is mislabeled or adulterated, because importing a misbranded drug into the United States violates 21 U.S.C. §331. [5] More practically, self-injecting an unverified sterile product without medical supervision creates genuine infection and overdose risk.

Insurance Coverage and Cost in New York

Vyleesi is a branded biologic-class peptide drug. Without insurance, the list price in 2024 was approximately $1,000 per kit (four autoinjectors). Palatin Technologies, the manufacturer, offers a savings card program for commercially insured patients that can reduce out-of-pocket cost significantly. [1]

New York's Medicaid program covers FDA-approved prescription drugs that appear on the state formulary. As of the date of this article, Vyleesi's Medicaid coverage status varies by plan and requires prior authorization documenting an HSDD diagnosis in a premenopausal woman. Patients should verify coverage with their insurer before prescribing. The FDA drug approval summary page and the Vyleesi prescribing information provide the documentation needed for prior-authorization requests. [1]

Summary of Legal Status at a Glance

New York patients have one lawful access pathway as of 2025: a prescription for brand-name Vyleesi from a New York-licensed clinician, filled at a licensed pharmacy. Compounded Bremelanotide is no longer permitted following the FDA's final decision removing it from the 503A bulks list. [2] Gray-market research-chemical sources carry no prescription oversight, no pharmaceutical-grade manufacturing assurance, and potential federal misbranding liability. The drug is not a controlled substance, so possession alone is not a criminal matter, but access without a legitimate prescription is both medically unsafe and legally irregular. Any clinician prescribing Vyleesi off-label (for men or for postmenopausal women) should document the clinical rationale and obtain documented informed consent in line with New York's medical practice standards. [9]